Wallace J I, Bekesi J G
Clin Immunol Immunopathol. 1986 Apr;39(1):179-86. doi: 10.1016/0090-1229(86)90218-7.
In a double-blind clinical trial, 61 immunodepressed males with persistent generalized lymphadenopathy (PGL) received one of two doses (1 or 3 g/day) of the immunomodulating drug inosine pranobex (INPX) or placebo for a period of 28 days. In the high-dose group, clinical improvement was reported by 11 of 21 patients (52%), within 5 months of the cessation of treatment. In contrast, 3 of 19 patients (16%) in the placebo group reported clinical improvement by that time. Patients receiving 3 g/day INPX showed a significant increase in NK cell activity by Day 14 and this elevation was still evident at the last follow-up examination 1 year after treatment. Increases in total T lymphocytes (T-11) and the percentage of T helper cells (T-4) were also observed. These responses were delayed and reached their peaks 2 months after the termination of drug treatment. The kinetics of these effects suggest that INPX stimulates the production of precursor cells and initiates a cascade of lymphocyte differentiation capable of producing long-term restoration of cell-mediated immunity. These data indicate that INPX may be beneficial to patients with PGL.
在一项双盲临床试验中，61名患有持续性全身性淋巴结病（PGL）的免疫抑制男性患者接受了两种剂量（1或3克/天）的免疫调节药物异丙肌苷（INPX）或安慰剂治疗，为期28天。在高剂量组中，21名患者中有11名（52%）在治疗停止后的5个月内报告有临床改善。相比之下，安慰剂组的19名患者中有3名（16%）在那时报告有临床改善。接受3克/天INPX治疗的患者在第14天时自然杀伤细胞（NK）活性显著增加，并且在治疗后1年的最后一次随访检查时这种升高仍然明显。还观察到总T淋巴细胞（T-11）和辅助性T细胞（T-4）百分比增加。这些反应出现延迟，在药物治疗终止后2个月达到峰值。这些效应的动力学表明，INPX刺激前体细胞的产生，并引发一系列能够长期恢复细胞介导免疫的淋巴细胞分化。这些数据表明，INPX可能对PGL患者有益。
